Enrollment timelines win and lose CRO contracts. HEKMA gives you AI-matched patient populations, data-backed feasibility, and white-label CTMS, so you stop estimating and start guaranteeing.
75% of global clinical trials are run by CROs, and 85% still miss their enrollment targets. (Tufts CSDD / Thermo Fisher)
3×
fewer screen failures with AI pre-screening
5 days
feasibility report from protocol receipt
60% → 20%
screen failure rate with Hekma patients
Weeks
not months to deploy white-label CTMS
The Industry Problem
0%
Enrollment decline
non-oncology Phase 3, 2012–2023
0%
Screen failure rate
industry average
$0K
Daily delay cost
to the sponsor
"Patient recruitment is not your product, it is your constraint. You win bids by promising timelines, but every timeline depends on patients showing up at sites."
McKinsey Global Institute, CRO Enrollment Study 2024
The tools available to most CROs today: site-based outreach, investigator networks, social media ads, were built for a world where patients lived near trial sites, had time, and knew trials existed. That world is gone.
Sources: McKinsey 2024, Tufts Center for the Study of Drug Development
85%
of CRO-run trials miss
their enrollment targets
Four steps from protocol receipt to pre-screened patients arriving at your sites.
Provide your trial protocol or we pull it directly from ClinicalTrials.gov. Our AI parses all inclusion and exclusion criteria automatically, no manual data entry.
Protocol loaded in under 1 hour.
HEKMA runs your criteria against hospital EHRs, PAG communities, and the H360 database. A tiered match report returns with confidence levels at 100%, 80%, and 50%.
Population report with 3-tier confidence.
The match report becomes your feasibility evidence. Your proposal goes in with real patient population data, not estimates. That is how you differentiate from every other bidder.
Data-backed bid, improved win rate.
We run the recruitment campaigns. Pre-screened candidates with eligibility scores arrive at your sites. Your coordinators enroll, not screen. Screen failure drops from 60% to under 20%.
Coordinators enroll, not screen.
Protocol Upload
< 1 hour
Population Report
5 business days
Bid Submitted
With real data
First Patient
Weeks, not months
Give us one trial protocol. We will show you the patient population before you commit to anything.
Replace your stack of disconnected tools with one platform that owns the full recruitment lifecycle.
Social media ads, unqualified responses, 60% screen failure
EHR matching and AI summarisation: only likely-eligible patients surface
Screen failure: 60% to under 20%
Internal feasibility estimates, educated guesses
Real patient population counts against your specific I/E criteria
Data-backed bid, win rate improves
Veeva CTMS at $250K minimum, 6 to 12 month implementation
CTMS live in days, white-label, connected to the recruitment layer
Trial running before competitors set up
Limited network for rare disease and CNS indications
H360 patient app and 50+ PAG rare disease communities
Find patients no site network can reach
| What You Need | Typical Tools | Hekma Advantage |
|---|---|---|
| Patient identification | Manual site queries | AI-matched EHR networks |
| Pre-screening | Fragmented spreadsheets | Automated clinical logic |
| Feasibility intelligence | Estimates and guesses | Verified patient counts |
| Trial execution system | Heavy, legacy CTMS | Cloud-native, rapid setup |
| Rare disease finding | Low visibility | Global specialty networks |
No more guessing. No more disconnected point solutions. No more integration tax.
AI-driven matching engine that scans global EHR networks to find high-probability candidates before they even hit the site.
A next-generation CTMS built for speed, transparency, and the rigors of modern decentralized or hybrid trials.
Point solutions solve one step. HEKMA owns identification, matching, summarisation, execution, and engagement in one platform with one data layer. No more integration tax, no more gaps.
Network density across four major indication families, built over years of EHR and PAG partnerships.
Heart failure, hypertension, AFib, atherosclerosis. Large patient pools, high trial volume, deepest hospital EHR coverage.
Solid tumors, hematologic malignancies, immuno-oncology. Deepest EHR network coverage across our hospital partner network.
Alzheimer's, Parkinson's, MS, depression, rare neurological. Complex I/E criteria are where HEKMA's AI matching specialises.
Ultra-specific patient populations where traditional site outreach consistently fails. H360 and 50+ PAG communities bridge the gap.
The matching marketplace for trial sites and CROs to find and pre-qualify candidates instantly.
Learn MoreThe single source of truth for global trial management, built for the precision era.
Explore PlatformCompliance and Regulatory Standards
Give us one trial protocol. We will run it against our network and show you the patient population size, match confidence breakdown, and estimated time to first patient, before you commit to anything.